These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 16918471)

  • 21. Cytochrome P450 networks in chemical space.
    Lee S; Kim D
    Arch Pharm Res; 2010 Sep; 33(9):1361-74. PubMed ID: 20945135
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of ginseng components on c-DNA-expressed cytochrome P450 enzyme catalytic activity.
    Henderson GL; Harkey MR; Gershwin ME; Hackman RM; Stern JS; Stresser DM
    Life Sci; 1999; 65(15):PL209-14. PubMed ID: 10574228
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Generation and validation of rapid computational filters for cyp2d6 and cyp3a4.
    Ekins S; Berbaum J; Harrison RK
    Drug Metab Dispos; 2003 Sep; 31(9):1077-80. PubMed ID: 12920160
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fluorometric high-throughput screening for inhibitors of cytochrome P450.
    Miller VP; Stresser DM; Blanchard AP; Turner S; Crespi CL
    Ann N Y Acad Sci; 2000; 919():26-32. PubMed ID: 11083094
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinically important pharmacokinetic drug-drug interactions: role of cytochrome P450 enzymes.
    Tanaka E
    J Clin Pharm Ther; 1998 Dec; 23(6):403-16. PubMed ID: 10048501
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytochrome P450 and Non-Cytochrome P450 Oxidative Metabolism: Contributions to the Pharmacokinetics, Safety, and Efficacy of Xenobiotics.
    Foti RS; Dalvie DK
    Drug Metab Dispos; 2016 Aug; 44(8):1229-45. PubMed ID: 27298339
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chemical proteomic probes for profiling cytochrome p450 activities and drug interactions in vivo.
    Wright AT; Cravatt BF
    Chem Biol; 2007 Sep; 14(9):1043-51. PubMed ID: 17884636
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of metabolites in predicting drug-drug interactions: focus on irreversible cytochrome P450 inhibition.
    VandenBrink BM; Isoherranen N
    Curr Opin Drug Discov Devel; 2010 Jan; 13(1):66-77. PubMed ID: 20047147
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structural basis of selective cytochrome P450 inhibition.
    Halpert JR
    Annu Rev Pharmacol Toxicol; 1995; 35():29-53. PubMed ID: 7598496
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytochrome P450 Structure, Function and Clinical Significance: A Review.
    Manikandan P; Nagini S
    Curr Drug Targets; 2018; 19(1):38-54. PubMed ID: 28124606
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Electrochemistry of cytochromes p450: analysis of current-voltage characteristics of electrodes with immobilized cytochromes p450 for the screening of substrates and inhibitors.
    Shumyantseva VV; Bulko TV; Kuznetsova GP; Samenkova NF; Archakov AI
    Biochemistry (Mosc); 2009 Apr; 74(4):438-44. PubMed ID: 19463098
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Survey of Machine Learning Techniques for Prediction of the Isoform Specificity of Cytochrome P450 Substrates.
    Xiong Y; Qiao Y; Kihara D; Zhang HY; Zhu X; Wei DQ
    Curr Drug Metab; 2019 May; 20(3):229-235. PubMed ID: 30338736
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of novel substrates for human cytochrome P450 2J2.
    Lee CA; Neul D; Clouser-Roche A; Dalvie D; Wester MR; Jiang Y; Jones JP; Freiwald S; Zientek M; Totah RA
    Drug Metab Dispos; 2010 Feb; 38(2):347-56. PubMed ID: 19923256
    [TBL] [Abstract][Full Text] [Related]  

  • 34. WhichCyp: prediction of cytochromes P450 inhibition.
    Rostkowski M; Spjuth O; Rydberg P
    Bioinformatics; 2013 Aug; 29(16):2051-2. PubMed ID: 23740742
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development.
    Zhou SF; Zhou ZW; Yang LP; Cai JP
    Curr Med Chem; 2009; 16(27):3480-675. PubMed ID: 19515014
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prediction of cytochrome P450 2B6-substrate interactions using pharmacophore ensemble/support vector machine (PhE/SVM) approach.
    Leong MK; Chen TH
    Med Chem; 2008 Jul; 4(4):396-406. PubMed ID: 18673154
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition and induction of human cytochrome P450 (CYP) enzymes.
    Pelkonen O; Mäenpää J; Taavitsainen P; Rautio A; Raunio H
    Xenobiotica; 1998 Dec; 28(12):1203-53. PubMed ID: 9890159
    [No Abstract]   [Full Text] [Related]  

  • 38. Computational identification and binding analysis of orphan human cytochrome P450 4X1 enzyme with substrates.
    Kumar S
    BMC Res Notes; 2015 Jan; 8():9. PubMed ID: 25595103
    [TBL] [Abstract][Full Text] [Related]  

  • 39. From electrochemistry to enzyme kinetics of cytochrome P450.
    Shumyantseva VV; Kuzikov AV; Masamrekh RA; Bulko TV; Archakov AI
    Biosens Bioelectron; 2018 Dec; 121():192-204. PubMed ID: 30218927
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Catalytic assays for human cytochrome P450: an introduction.
    Chang TK; Waxman DJ
    Methods Mol Biol; 2006; 320():73-83. PubMed ID: 16719375
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.